Modified vaccinia ankara

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Modified vaccinia ankara
Accession Number
DB15483
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Description
Not Available
Synonyms
  • Modified Vaccinia Virus (Ankara-Bavarian Nordic)
  • MVA
  • MVA-BN
  • Vaccinia strain modified ankara
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImvamuneSuspensionSubcutaneousBavarian Nordic As2015-06-15Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
TU8J357395
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Abetimus.
ActeosideThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Afelimomab.
AlclometasoneThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldesleukin.
AldosteroneThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldosterone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionAtopic Dermatitis (AD) / Pollen Allergy1
1CompletedPreventionEbola Virus Infection / Immunizations1
1CompletedPreventionEbola Virus Infection / Marburg Virus Disease1
1CompletedPreventionEbola / Ebola Zaire1
1CompletedPreventionHealthy Volunteers4
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections5
1CompletedPreventionInfections, Respiratory Syncytial Virus1
1CompletedPreventionPlasmodium Infections2
1CompletedPreventionSmallpox3
1CompletedPreventionVariola Major (Smallpox)1
1CompletedPreventionYellow Fever1
1CompletedSupportive CareHealthy, no Evidence of Disease / Infections, Cytomegalovirus1
1CompletedTreatmentAndrogen-insensitive Prostate Cancer1
1CompletedTreatmentBreast Cancer2
1CompletedTreatmentBreast Cancer / Lung Cancers / Ovarian Cancer / Prostate Cancer / Tumors (Others)1
1CompletedTreatmentDisorders, Lymphoproliferative / Head and Neck Carcinoma / Malignant Lymphomas / Malignant Neoplasm of Stomach / Nonneoplastic Condition1
1CompletedTreatmentEpstein-Barr Virus Infections / Nasopharyngeal Neoplasms1
1Not Yet RecruitingTreatmentBreast Cancer / Lung Cancers / Ovarian Cancer / Prostate Cancer / Tumors (Others)1
1RecruitingOtherHuman Immunodeficiency Virus (HIV) Infections1
1TerminatedPreventionHuman Immunodeficiency Virus (HIV) Infections / Smallpox1
1WithdrawnPreventionAtopic Dermatitis (AD) / Smallpox1
1WithdrawnPreventionInfections, Respiratory Syncytial Virus1
1, 2Active Not RecruitingPreventionHealthy Volunteers1
1, 2CompletedNot AvailableHealthy Volunteers1
1, 2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedPreventionPlasmodium Infections1
1, 2CompletedPreventionSmallpox2
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1, 2RecruitingSupportive CareCytomegaloviral Infection / Cytomegalovirus Positive / Hematopoietic Cell Transplant Recipient / Hematopoietic Cell Transplantation Recipient1
1, 2RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC) / Intermediate Risk Prostate Cancer1
2Active Not RecruitingPreventionEbola Virus Disease / Healthy Volunteers1
2Active Not RecruitingSupportive CareAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Cytomegaloviral Infection / Lymphadenopathy / Lymphoma, Hodgkins / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage I Non-Small Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Immunogenicity / Safety / Vaccines1
2CompletedPreventionAtopic Dermatitis (AD)1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionPlasmodium Infections2
2CompletedPreventionSmallpox7
2CompletedPreventionTuberculosis Infection1
2CompletedPreventionVariola Major (Smallpox)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingPreventionEbola Virus Disease1
2RecruitingSupportive CareAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukaemias (ALL) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingSupportive CareAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Cytomegalovirus Positive / Donor / Hematopoietic and Lymphoid Cell Neoplasm / Hematopoietic Cell Transplant Recipient / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
2WithdrawnSupportive CareAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Agnogenic Myeloid Metaplasia / Bone Marrow Transplantation Recipient / Chronic Lymphocytic Leukaemia (CLL) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic Cell Transplantation Recipient / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentBreast Cancer1
3Active Not RecruitingPreventionHemorrhagic Fever, Ebola1
3Active Not RecruitingPreventionSmallpox1
3CompletedPrevention18-42 Year Old Healthy Vaccinia-naïve Subjects1
3CompletedPreventionSmallpox1
3RecruitingPreventionEbola1
3RecruitingPreventionEbola Virus Disease1
3RecruitingPreventionMonkeypox Virus Infection1
4CompletedPreventionVaccinations1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on August 30, 2019 11:59 / Updated on May 30, 2020 00:22

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates